{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:42:12Z","timestamp":1792604532299,"version":"4.5.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R44HL169085"],"award-info":[{"award-number":["R44HL169085"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Prescription and claims data indicate that hydroxyurea (HU) adherence is low among youth with sickle cell disease (SCD). Electronic monitors (EM) are a gold standard measure, yet existing models have significant drawbacks that limit their use in youth with SCD. We developed a small, cellular-connected EM that is compatible with both liquid and capsule HU formulation bottles. In testing this EM among a sample of adolescents and young adults and caregivers of young children with SCD, we found that the EM is feasible and acceptable among youth with SCD and caregivers of young children with SCD in the short-term. We also found that the EM are useful for determining HU adherence and gained user insights that may improve their use longer-term. Future studies should examine the EM ability to determine which youth with SCD could most benefit from HU adherence intervention and treatment escalation in those with optimized adherence.<\/jats:p>","DOI":"10.1371\/journal.pone.0358450","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:27:17Z","timestamp":1792603637000},"page":"e0358450","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["A liquid- and capsule-compatible hydroxyurea electronic monitor to identify non-adherent youth with sickle cell disease"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5935-6829","authenticated-orcid":true,"given":"Anyssa","family":"Young","sequence":"first","affiliation":[{"name":"Nationwide Children\u2019s Hospital","place":["Columbus, Ohio, United States of America"],"department":["Abigail Wexner Research Institute"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nate","family":"Goldfarb","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital","place":["Columbus, Ohio, United States of America"],"department":["Abigail Wexner Research Institute"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"McGann","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology, Lifespan Comprehensive Sickle Cell Center","place":["Providence, Rhode Island, United States of America"],"department":["Hasbro Children\u2019s Hospital"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif M.","family":"Badawy","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Stem Cell Transplant","place":["Chicago, Illinois, United States of America"],"department":["Ann & Robert H. Lurie Children\u2019s Hospital of Chicago"]},{"name":"Northwestern University Feinberg School of Medicine","place":["Chicago, Illinois, United States of America"],"department":["Department of Pediatrics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Seiguer","sequence":"additional","affiliation":[{"name":"Scene Health","place":["Brooklandville, Maryland, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savannah","family":"Winkler","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Stem Cell Transplant","place":["Chicago, Illinois, United States of America"],"department":["Ann & Robert H. Lurie Children\u2019s Hospital of Chicago"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Huerta","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Stem Cell Transplant","place":["Chicago, Illinois, United States of America"],"department":["Ann & Robert H. Lurie Children\u2019s Hospital of Chicago"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbel","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Brown University Health, Pediatric Hematology and Oncology","place":["Providence, Rhode Island, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saige","family":"Armistead","sequence":"additional","affiliation":[{"name":"Scene Health","place":["Brooklandville, Maryland, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-8139","authenticated-orcid":true,"given":"Susan","family":"Creary","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital","place":["Columbus, Ohio, United States of America"],"department":["Abigail Wexner Research Institute"]},{"name":"Oncology, and Bone Marrow Transplant, Nationwide Children\u2019s Hospital","place":["Columbus, Ohio, United States of America"],"department":["Department of Hematology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"pone.0358450.ref001","unstructured":"CDC. Data and Statistics on Sickle Cell Disease Centeres for Disease Control and Prevention. [cited 2024 May 15]. Available from: https:\/\/www.cdc.gov\/sickle-cell\/data\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/data.html"},{"issue":"9","key":"pone.0358450.ref002","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/17512433.2024.2390915","article-title":"Hydroxyurea in the sickle cell disease modern era","volume":"17","author":"C Riley","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"pone.0358450.ref003","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30332","article-title":"Adherence to hydroxyurea and clinical outcomes among children with sickle cell anemia","volume":"70","author":"SL Reeves","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"pone.0358450.ref004","doi-asserted-by":"crossref","DOI":"10.2196\/13452","article-title":"A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study","volume":"7","author":"S Creary","year":"2019","journal-title":"JMIR Mhealth Uhealth"},{"issue":"23","key":"pone.0358450.ref005","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.1182\/bloodadvances.2023010670","article-title":"A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease","volume":"7","author":"JS Hankins","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"pone.0358450.ref006","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/ajh.21968","article-title":"Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease","volume":"86","author":"SD Candrilli","year":"2011","journal-title":"Am J Hematol"},{"issue":"6","key":"pone.0358450.ref007","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29607","article-title":"Impact of hydroxyurea dose and adherence on hematologic outcomes for children with sickle cell anemia","volume":"69","author":"SE Creary","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"pone.0358450.ref008","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28250","article-title":"Measuring hydroxyurea adherence by pharmacy and laboratory data compared with video observation in children with sickle cell disease","volume":"67","author":"S Creary","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"pone.0358450.ref009","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"L Osterberg","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0358450.ref010","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jpeds.2011.05.018","article-title":"Electronic measurement of medication adherence in pediatric chronic illness: a review of measures","volume":"159","author":"LM Ingerski","year":"2011","journal-title":"J Pediatr"},{"key":"pone.0358450.ref011","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.2147\/PPA.S431595","article-title":"Feasibility of Electronic Medication Monitoring Among Adolescents and Emerging Adults with Sickle Cell Disease","volume":"17","author":"AK Hildenbrand","year":"2023","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"pone.0358450.ref012","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1046\/j.1365-2125.1998.00730.x","article-title":"Trying to improve compliance with prophylactic penicillin therapy in children with sickle cell disease","volume":"45","author":"M Berkovitch","year":"1998","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"pone.0358450.ref013","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s12185-016-2027-x","article-title":"Adherence to hydroxyurea medication by children with sickle cell disease (SCD) using an electronic device: a feasibility study","volume":"104","author":"S Inoue","year":"2016","journal-title":"Int J Hematol"},{"issue":"1","key":"pone.0358450.ref014","doi-asserted-by":"crossref","DOI":"10.1097\/MPH.0000000000001997","article-title":"Use of Wise Device Technology to Measure Adherence to Hydroxyurea Therapy in Youth With Sickle Cell Disease","volume":"43","author":"LM Ingerski","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"pone.0358450.ref015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304644","article-title":"Study protocol for ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness): Using small business partnerships to deliver a scalable and novel hydroxyurea adherence solution to youth with sickle cell disease","volume":"19","author":"J Walden","year":"2024","journal-title":"PLoS One"},{"key":"pone.0358450.ref016","doi-asserted-by":"crossref","first-page":"2333393617742282","DOI":"10.1177\/2333393617742282","article-title":"Employing a Qualitative Description Approach in Health Care Research","volume":"4","author":"C Bradshaw","year":"2017","journal-title":"Glob Qual Nurs Res"},{"issue":"6","key":"pone.0358450.ref017","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/pbc.24931","article-title":"A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease","volume":"61","author":"SE Creary","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"pone.0358450.ref018","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1471-2458-11-92","article-title":"Measuring adherence to antiretroviral therapy in northern Tanzania: feasibility and acceptability of the Medication Event Monitoring System","volume":"11","author":"RA Lyimo","year":"2011","journal-title":"BMC Public Health"},{"issue":"3","key":"pone.0358450.ref019","article-title":"Effect of electronic adherence monitoring on adherence and outcomes in chronic conditions: A systematic review and meta-analysis","volume":"17","author":"AHY Chan","year":"2022","journal-title":"PLoS One"},{"issue":"3","key":"pone.0358450.ref020","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12160-014-9595-x","article-title":"Does electronic monitoring influence adherence to medication? Randomized controlled trial of measurement reactivity","volume":"48","author":"S Sutton","year":"2014","journal-title":"Ann Behav Med"},{"issue":"5","key":"pone.0358450.ref021","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1177\/0193945911427153","article-title":"Practical and analytic issues in the electronic assessment of adherence","volume":"34","author":"P Cook","year":"2012","journal-title":"West J Nurs Res"},{"issue":"1","key":"pone.0358450.ref022","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/07853890.2022.2044509","article-title":"Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents","volume":"54","author":"PS Reddy","year":"2022","journal-title":"Ann Med"},{"issue":"6","key":"pone.0358450.ref023","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/ejh.12878","article-title":"Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease","volume":"98","author":"SM Badawy","year":"2017","journal-title":"Eur J Haematol"},{"issue":"4","key":"pone.0358450.ref024","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30878","article-title":"Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT) efficacy trial: Community health worker support may increase hydroxyurea adherence of youth with sickle cell disease","volume":"71","author":"NS Green","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"pone.0358450.ref025","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s43856-024-00552-5","article-title":"Hydroxyurea mobile directly observed therapy versus standard monitoring in patients with sickle cell anemia: a phase 2 randomized trial","volume":"4","author":"P Sasi","year":"2024","journal-title":"Commun Med (Lond)"},{"issue":"5","key":"pone.0358450.ref026","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease","volume":"376","author":"KI Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0358450.ref027","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A Phase 3 Trial of l-Glutamine in Sickle Cell Disease","volume":"379","author":"Y Niihara","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0358450.ref028","unstructured":"Lin K. Will the High Price of Gene Therapy for Sickle Cell Disease Put This Cure out of Reach? American Family Physician Community Blog. 2023 [cited 2023 Dec 12]. Available from: https:\/\/www.aafp.org\/pubs\/afp\/afp-community-blog\/entry\/will-the-high-price-of-gene-therapy-for-sickle-cell-disease-put-this-cure-out-of-reach.html"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0358450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:27:22Z","timestamp":1792603642000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0358450"}},"subtitle":[],"editor":[{"given":"J Francis","family":"Borgio","sequence":"first","affiliation":[{"name":"Imam Abdulrahman Bin Faisal University","place":["SAUDI ARABIA"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0358450","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]}}}